



C I R M

CALIFORNIA INSTITUTE FOR
REGENERATIVE MEDICINE

Revised Research Budget Forecast

Rosa Canet-Avilés, CSO

JUNE 25, 2026

Aligning Long-Term Investment Strategy with Patient Impact

- The **original forecast** with the SAF was through 2030/31 to quickly deploy CIRM funds
- The **proposed forecast** aims to **optimize impact over time**, **align funding cadence with scientific opportunity**, and **preserve flexibility** for emerging technologies & partnerships

Why Revisit the Forecast Now?

Proposed 8-year path focuses on mission delivery, not simply pace of spend

Original 6-Year Projection

- **Compressed** funding deployment
- **Less flexibility** for emerging opportunities
- More **schedule-driven** investment
- **Reduced continuity** across the pipeline



Proposed 8-Year Projection

- **Readiness-based** funding deployment
- Greater strategic **flexibility**
- More **responsive** to emerging opportunities
- Stronger pipeline **continuity**

Previous Financial Outlook

Funding through FY2030/31

Pillar	2026/27	2027/28	2028/29	2029/30	2030/31	Total
CLIN	\$135	\$235	\$135	\$135	\$235	\$875
PDEV	\$230	\$230	\$170	\$120	\$90	\$840
DISC	\$162	\$162	\$162	\$162	\$162	\$810
EDUC	\$119.5	\$182.5	\$2.5	\$2.5	\$2.5	\$309.5
INFR*	\$10	\$40	\$87	\$10	\$10	\$171.5*
TOTAL	\$656.5	\$849.5	\$556.5	\$429.5	\$499.5	\$2,991.5

*Does not include funds for Accessibility & Affordability
 Numbers in the table are in millions of dollars (\$000,000); Minor variances due to rounding

Current Financial Outlook

Funding through FY2032/33

Pillar	2026/27	2027/28	2028/29	2029/30	2030/31	2031/32	2032/33	Total
CLIN	\$160	\$170	\$170	\$170	\$160	\$130	\$94.1	\$1,054
PDEV	\$146	\$128.5	\$143.5	\$112.5	\$112.5	\$112.5	\$45	\$800.5
DISC	\$136.5	\$84.7	\$159	\$75	\$159	\$25	\$0	\$639.2
EDUC	\$200.5	\$101.5	\$2.5	\$2.5	\$2.5	\$2.4	\$0	\$311.9
INFR*	\$19	\$86	\$117	\$10	\$10	\$0	\$0	\$242*
TOTAL	\$662	\$570.7	\$592	\$370	\$444	\$269.9	\$139.1	\$3,048

*Does not include funds for Accessibility & Affordability
 Numbers in the table are in millions of dollars (\$000,000); Minor variances due to rounding

Summary of Forecast Changes

PILLAR	Key Changes & Rationale
CLIN	• Consolidate clinical programs, with future late-stage strategy informed by the September portfolio review • Add funding to later years to preserve flexibility for emerging opportunities
PDEV	• Rebalance annual funding levels to reflect expected investment in rare/gene pdev through RAPID • Adjust award mix and timing to align with portfolio priorities • Shift a portion of funding to later years to preserve flexibility for emerging opportunities
DISC	• Move DISC4 to a less frequent cadence to maximize network value, data utilization, and partnership opportunities
EDUC	• Accelerated Scholars funding 1 year
INFR	• Allocated funding for Alpha Clinics



CIRM

CALIFORNIA INSTITUTE FOR
REGENERATIVE MEDICINE

Community Care Centers of Excellence Site Visits

Patient Access Team

JUNE 25, 2026

Overview



INFR8 Funding Program – 3 CCCEs

Community Health System	Fresno Community Hospital, PD Haifaa Abdulhaq Service Area: Central Valley Launched March 2026
Lundquist Institute	Harbor UCLA Hospital, PD Christina Wang Service Area: South Los Angeles / South Bay Launched April 2026
Loma Linda University	Loma Linda University Medical Center, PD Hisham Abdel-Azim Service Area: Inland Empire Launched March 2026



CIRM Team Site Visits

- Jon JT Thomas
- Grants Management Team (Jennifer Lewis, Alex Caraballo)
- Communications Team (Amy Adams, Scott Hadly)
- Programs Team (Joseph Gold)
- Patient Access Team (Geoff Lomax, Nimit Ruparel, Cameron Malik, Shyam Patel)


Community Health System

Clovis/Fresno, CA

Building CGT Clinical Trial Capabilities

- State-of-the-art cancer facilities
- Onboarding all major commercial CAR-T products
- Building CGT manufacturing facility
- Collaborators: UC Davis, UCSF
- Community Partners: Blood Cancer United, Fresno Center

Kite CAR-T Authorized Treatment Centers



Loma Linda University

Loma Linda, CA

Expanding CGT Trial Capabilities

- Authorized Treatment Center for multiple commercial CGTs
- Treatment site for cell and gene therapy trials for neurological disorders (AskBio, Neurona)
- Centralized clinical research administrative unit
- Building CGT manufacturing facility
- Collaborators: Cedars Sinai, UC Davis
- Community Partners: El Sol, HARC, Sac Health



The Lundquist Institute

Torrance, CA


Building CGT Trial Capabilities

- Exclusively focused on ambulatory setting for CGT trials
- Renovating pharmacy and patient rooms to support CGT trials
- Actively discussing with CGT trial sponsors
- Collaborators: UCLA, Charles Drew University
- Community partners: RFK Institute, South Central Prevention Coalition & Axis Advocacy



Thank you, Geoff Lomax
20+ years of service to CIRM

Geoff led the scoping,
development and launch of the
CCCE Program





Thank you

C I R M